Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Pharmaceutical Manufacturing Market, By Drug Development Type
7.1. Pharmaceutical Manufacturing Market, by Drug Development Type, 2020-2030
7.1.1. Outsource
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. In-house
7.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Pharmaceutical Manufacturing Market, By Formulation
8.1. Pharmaceutical Manufacturing Market, by Formulation, 2020-2030
8.1.1. Tablets
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Capsules
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Injectable
8.1.3.1. Market Revenue and Forecast (2016-2030)
8.1.4. Sprays
8.1.4.1. Market Revenue and Forecast (2016-2030)
8.1.5. Suspensions
8.1.5.1. Market Revenue and Forecast (2016-2030)
8.1.6. Powders
8.1.6.1. Market Revenue and Forecast (2016-2030)
8.1.7. Other Formulations
8.1.7.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Pharmaceutical Manufacturing Market, By Route of Administration
9.1. Pharmaceutical Manufacturing Market, by Route of Administration, 2020-2030
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. Topical
9.1.2.1. Market Revenue and Forecast (2016-2030)
9.1.3. Parenteral
9.1.3.1. Market Revenue and Forecast (2016-2030)
9.1.4. Inhalations
9.1.4.1. Market Revenue and Forecast (2016-2030)
9.1.5. Other Routes of Administration
9.1.5.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global Pharmaceutical Manufacturing Market, By Therapy Area
10.1. Pharmaceutical Manufacturing Market, by Therapy Area, 2020-2030
10.1.1. Cardiovascular Diseases
10.1.1.1. Market Revenue and Forecast (2016-2030)
10.1.2. Pain
10.1.2.1. Market Revenue and Forecast (2016-2030)
10.1.3. Diabetes
10.1.3.1. Market Revenue and Forecast (2016-2030)
10.1.4. Cancer
10.1.4.1. Market Revenue and Forecast (2016-2030)
10.1.5. Respiratory Diseases
10.1.5.1. Market Revenue and Forecast (2016-2030)
10.1.6. Other Diseases
10.1.6.1. Market Revenue and Forecast (2016-2030)
Chapter 11. Global Pharmaceutical Manufacturing Market, By Prescription
11.1. Pharmaceutical Manufacturing Market, by Prescription, 2020-2030
11.1.1. Prescription Medicines
11.1.1.1. Market Revenue and Forecast (2016-2030)
11.1.2. Over-the-counter (OTC) Medicines
11.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 12. Global Pharmaceutical Manufacturing Market, By Age Group
12.1. Pharmaceutical Manufacturing Market, by Age Group, 2020-2030
12.1.1. Children & Adolescents
12.1.1.1. Market Revenue and Forecast (2016-2030)
12.1.2. Adults
12.1.2.1. Market Revenue and Forecast (2016-2030)
12.1.3. Geriatric
12.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 13. Global Pharmaceutical Manufacturing Market, By Distribution Channel
13.1. Pharmaceutical Manufacturing Market, by Distribution Channel, 2020-2030
13.1.1. Retail
13.1.1.1. Market Revenue and Forecast (2016-2030)
13.1.2. Non-retail
13.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 14. Global Pharmaceutical Manufacturing Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.1.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.1.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.1.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.1.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.1.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.1.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.1.8.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.1.8.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.1.8.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.1.8.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.1.8.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.1.8.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.1.9.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.1.9.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.1.9.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.1.9.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.1.9.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.1.9.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.2. Europe
14.2.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.2.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.2.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.2.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.2.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.2.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.2.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.2.8.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.2.8.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.2.8.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.2.8.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.2.8.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.2.8.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.2.9.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.2.9.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.2.9.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.2.9.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.2.9.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.2.9.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.2.10.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.2.10.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.2.10.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.2.10.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.2.10.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.2.10.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.2.11.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.2.11.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.2.11.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.2.11.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.2.11.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.2.11.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.3.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.3.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.3.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.3.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.3.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.3.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.3.8.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.3.8.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.3.8.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.3.8.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.3.8.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.3.8.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.3.9.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.3.9.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.3.9.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.3.9.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.3.9.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.3.9.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.3.10.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.3.10.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.3.10.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.3.10.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.3.10.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.3.10.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.3.11.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.3.11.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.3.11.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.3.11.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.3.11.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.3.11.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.4.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.4.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.4.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.4.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.4.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.4.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.4.8.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.4.8.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.4.8.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.4.8.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.4.8.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.4.8.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.4.9.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.4.9.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.4.9.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.4.9.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.4.9.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.4.9.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.4.10.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.4.10.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.4.10.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.4.10.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.4.10.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.4.10.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.4.11.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.4.11.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.4.11.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.4.11.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.4.11.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.4.11.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.5.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.5.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.5.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.5.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.5.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.5.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.5.8.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.5.8.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.5.8.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.5.8.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.5.8.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.5.8.7. Market Revenue and Forecast, by Age Group (2016-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Drug Development Type (2016-2030)
14.5.9.2. Market Revenue and Forecast, by Formulation (2016-2030)
14.5.9.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
14.5.9.4. Market Revenue and Forecast, by Therapy Area (2016-2030)
14.5.9.5. Market Revenue and Forecast, by Prescription (2016-2030)
14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2016-2030)
14.5.9.7. Market Revenue and Forecast, by Age Group (2016-2030)
Chapter 15. Company Profiles
15.1. F. Hoffmann-La Roche Ltd
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Novartis AG
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. GlaxoSmithKline plc
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Pfizer, Inc.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. AstraZeneca
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Merck & Co., Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Johnson & Johnson
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Sanofi SA
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Eli Lilly and Company
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Lonza
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
Glossary of Terms